Skip to main content

MediciNova, Inc.

corporate_fare Company Profile

MediciNova, Inc.

MNOV·NASDAQ·Life Sciences·CIK 0001226616

We are a biopharmaceutical company focused on developing new treatments for serious diseases where current medical options are insufficient, with a commercial focus on the United States (U.S.) market. Our current strategy involves developing MN-166 (ibudilast) for neurological and other disorders, including progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and the prevention of acute respiratory distress syndrome (ARDS). We are also developing MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD) and hypertriglyceridemia. For progressive multiple sclerosis, we completed a Phase 2b clinical trial of MN-166 (ibudilast) for relapsing MS, which showed positive safety and neuroprotective efficacy indicators, suggesting potential for progressive MS. We collaborated with investigators on a Phase 2b clinical trial of MN-166 (ibudilast) in primary progressive and secondary progressive MS, conducted by NeuroNEXT and funded by the National Institute of Health's (NIH) National Institute of Neurological Diseases and Stroke (NINDS). This trial, known as SPRINT-MS, completed randomization of 255 subjects in 2015, exceeding the planned goal of 250 subjects. In October 2017, we announced positive top-line results from SPRINT-MS, which achieved its primary endpoints of whole brain atrophy and safety and tolerability. MN-166 (ibudilast) showed a statistically significant 48% reduction in the rate of whole brain atrophy progression compared to placebo (p=0.04), measured by magnetic resonance imaging (MRI) analysis using brain parenchymal fraction (BPF), with no increased rate of serious adverse events in the MN-166 (ibudilast) group. In February 2018, we announced positive clinical efficacy trends from this trial regarding the secondary endpoint of confirmed disability progression.

MediciNova, Inc. (NASDAQ:MNOV) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 10 items for MNOV at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 10 most recent items scored 7 or higher, the top rating is 8/10, with 3 rated 8 or above. Recent SEC coverage for MNOV spans 10-Q, SCHEDULE 13D/A, 8-K, PRE 14A.

Recent high-impact activity:

  • MediciNova CFO Resigns; CEO Iwaki Takes Over as Acting Finance Chief
  • 3D Investment Partners Sells 640K MediciNova Shares, Adds TRS Exposure
  • MN-001 Hits Statistically Significant HDL-C and HDL-P Boosts in Phase 2 NAFLD Trial
  • MediciNova Completes Double-Blind Phase of ALS Trial, Topline Data Due by Year-End
  • Shareholders Reject Proposal to Increase Authorized Shares by 147%

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$409.66K
Net Income
-$12M
Diluted EPS
-$0.24
Op. Cash Flow
-$9.81M
Free Cash Flow
-$9.81M
Operating Income
-$13.28M
Cash & Equivalents
$30.81M
Debt / Equity
0.00×
Net Margin
-29.29×
Shares Outstanding
49.22M sh
Source: 10-K · filed 2026-03-10 · accession 0001193125-26-100432

Short Interest & Short Volume

5.44 days to cover

FINRA reported short interest of 285,184 shares in MNOV as of the October 30, 2026 settlement, a 2.4% decrease from the prior period — about 5.4 days to cover at its recent average daily volume. On November 20, 2026, 74.1% of MNOV volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)285,184 shares as of October 30, 2026
Change vs prior period▼ 2.4%
Days to cover5.44 at avg daily volume of 52,467
Daily short volume (FINRA facilities)74.1% of 28,229 shares on November 20, 2026
5-day average short volume41.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with M →
$1.27
52-week range · as of 2026-11-12 $1.22 – $3.9
Market cap
$67.11M
Volume
49K (0.8× avg)
3-mo avg 61.2K
Live data · 2026-11-22 07:09 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed MNOV - Latest Insights

MNOV
Nov 12, 2026, 4:30 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.40
Real-time Price: $1.27 info
Change: -$0.130 (-9%) info
Market Cap: $67.115M info
MNOV
Sep 29, 2026, 5:00 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $1.92
Real-time Price: $1.27 info
Change: -$0.650 (-34%) info
Market Cap: $67.115M info
MNOV
Sep 28, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.41
Real-time Price: $1.27 info
Change: -$1.14 (-47%) info
Market Cap: $67.115M info
MNOV
Sep 24, 2026, 6:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.63
Real-time Price: $1.27 info
Change: -$1.36 (-52%) info
Market Cap: $67.115M info
MNOV
Jun 24, 2026, 4:38 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.33
Real-time Price: $1.27 info
Change: -$0.060 (-5%) info
Market Cap: $67.115M info
MNOV
May 26, 2026, 7:00 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.39
Real-time Price: $1.27 info
Change: -$0.120 (-9%) info
Market Cap: $67.115M info
MNOV
Apr 17, 2026, 4:57 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $1.46
Real-time Price: $1.27 info
Change: -$0.190 (-13%) info
Market Cap: $67.115M info
MNOV
Mar 10, 2026, 5:35 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.41
Real-time Price: $1.27 info
Change: -$0.140 (-10%) info
Market Cap: $67.115M info
MNOV
Mar 10, 2026, 5:15 PM EDT
Filing Type: 10-K
Importance Score:
7
Price at Filing: $1.41
Real-time Price: $1.27 info
Change: -$0.140 (-10%) info
Market Cap: $67.115M info
MNOV
Feb 20, 2026, 6:25 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.55
Real-time Price: $1.27 info
Change: -$0.280 (-18%) info
Market Cap: $67.115M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets